XBiotech
XBIT
50 hedge funds and large institutions have $37.5M invested in XBiotech in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 6
167% more call options, than puts
Call options by funds: $8K | Put options by funds: $3K
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
61% more capital invested
Capital invested by funds: $23.2M → $37.5M (+$14.3M)
9% more funds holding
Funds holding: 46 → 50 (+4)
1.1% more ownership
Funds ownership: 14.83% → 15.93% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$761K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$691K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$353K |
| 4 |
Morgan Stanley
New York
|
+$205K |
| 5 |
Goldman Sachs
New York
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$530K |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$132K |
| 3 |
AGM
Alpine Global Management
New York
|
-$91.5K |
| 4 |
Bank of New York Mellon
New York
|
-$89.2K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$66.4K |
XBIT Hedge Fund Activity: Q3 2024 in Review
50 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2024, worth a combined $37.5M — up 61% from $23.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XBIT positions and 5 closed out — a net gain of 4 holders — while 24 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $761K. The largest seller was Millennium Management, cutting an estimated $530K.
- 50 institutional investors held XBiotech (XBIT) as of Q3 2024, up from 46 in Q2 2024.
- Funds reported $37.5M of XBiotech stock for Q3 2024, up 61% quarter-over-quarter.
- 9 funds opened new XBiotech positions in Q3 2024 and 5 closed out, a net change of +4 holders.
- The largest XBiotech buyer in Q3 2024 was BlackRock, an estimated $761K added.
- The largest XBiotech seller in Q3 2024 was Millennium Management, an estimated $530K sold.
Based on aggregated 13F filings for Q3 2024.